Aerie Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Business and Strategic Update

Conference Call and Webcast Today, May 7, at 5:00 p.m. ET
Company to Review Additional Findings from Initial Rhopressa™ Phase 3 Registration Trial on Conference Call

IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--- Aerie Pharmaceuticals, Inc. (AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2015. The Company will host a live conference call and webcast at 5:00 p.m. Eastern Time today to discuss the Company’s financial results and provide a general business and strategic update. On the call, the Company also will discuss additional findings from its initial RhopressaTM Phase 3 registration trial, “Rocket 1,” along with expected paths forward for both Rhopressa™ and Roclatan™.

Published: 08 May 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Aerie Pharmaceuticals Inc ( AERI )

Calithera Biosciences Reports First Quarter 2015 Financial Results and Recent Highlights

Calithera to Host Conference Call Today at 4:30pm Eastern Time

SOUTH SAN FRANCISCO, Calif., May 7, 2015 -- Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the first quarter ended March 31, 2015. As of March 31, 2015, cash, cash equivalents and investments totaled $94.3 million.

Published: 08 May 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Calithera Biosciences Inc ( CALA )

Thomas Jefferson University Launches Major Head and Neck Cancer Study Utilizing Cesium-131 Where Current Standard of Care Treatments Have Failed

Successful Cesium-131 Cancer Treatment Results, as Reported by Other Institutions, Are Driving New Institutions to Offer Cesium-131 Therapy

RICHLAND, WA--(May 7, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the start of a new study of head and neck cancer patients being treated with IsoRay's Cesium-131 internal radiation (brachytherapy) cancer seeds. The study is being conducted at Thomas Jefferson University, a leading, highly recognized national institution in the cancer therapy field.

Published: 07 May 2015
Written by Editor
AMEX   Up on News   Project Update  
Read more: IsoRay Inc ( ISR )

Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results

TARRYTOWN, N.Y., May 6, 2015  -- Progenics Pharmaceuticals, Inc. (PGNX) today announced results of operations for the first quarter ended March 31, 2015.

"Our portfolio offers multiple opportunities to create value for our shareholders," stated Mark Baker, CEO of Progenics. "The recent positive CHMP opinion for subcutaneous RELISTOR, together with the upcoming U.S. NDA filing for the oral indication, highlight the multiple opportunities for growth in this important franchise. Our pivotal Phase 2b trial for Azedra is progressing as expected, and we remain on track to complete enrollment by year-end. For our prostate cancer programs, we are finalizing the protocol for our Phase 3 1404 imaging trial and evaluating opportunities to advance PSMA ADC following the completion of our successful Phase 2 trial. We are well-positioned to achieve our objectives, and remain focused on advancing these important programs through the clinic."

Published: 06 May 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Progenics Pharmaceuticals Inc ( PGNX )

Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies

Alliance Utilizes Fate's Hematopoietic Cell Programming Platform to Identify Small Molecule Modulators for Juno's Leading Genetically-Engineered T Cell Immunotherapies

SEATTLE and SAN DIEGO, May 6, 2015 -- Juno Therapeutics, Inc. (JUNO) and Fate Therapeutics, Inc. (FATE) announced today that they have executed a strategic research collaboration and license agreement to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product candidates to improve their therapeutic potential for cancer patients. The collaboration brings together Juno's industry-leading expertise in the development of chimeric antigen receptor (CAR) and T cell receptor (TCR) based cellular immunotherapies and Fate's innovative platform for programming the biological properties and in vivo therapeutic potential of hematopoietic cells.

Published: 06 May 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Fate Therapeutics Inc ( FATE )
  1. PlasmaTech Biopharmaceuticals Inc ( PTBI )
  2. Synageva BioPharma Corp ( GEVA )
  3. Abiomed Inc ( ABMD )
  4. CytRx Corporation ( CYTR )
  5. Nektar Therapeutics ( NKTR )